Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.

Brown JWL, Prados Carrasco F, Eshaghi A, Sudre CH, Button T, Pardini M, Samson RS, Ourselin S, Wheeler-Kingshott CAG, Jones JL, Coles AJ, Chard DT.

Mult Scler. 2019 Jun 6:1352458519852093. doi: 10.1177/1352458519852093. [Epub ahead of print]

PMID:
31169059
2.

Magnetisation transfer ratio abnormalities in primary and secondary progressive multiple sclerosis.

Brown JWL, Chowdhury A, Kanber B, Prados Carrasco F, Eshaghi A, Sudre CH, Pardini M, Samson RS, van de Pavert SH, Wheeler-Kingshott CG, Chard DT.

Mult Scler. 2019 Apr 8:1352458519841810. doi: 10.1177/1352458519841810. [Epub ahead of print]

PMID:
30957691
3.

Default Mode Network Structural Integrity and Cerebellar Connectivity Predict Information Processing Speed Deficit in Multiple Sclerosis.

Savini G, Pardini M, Castellazzi G, Lascialfari A, Chard D, D'Angelo E, Gandini Wheeler-Kingshott CAM.

Front Cell Neurosci. 2019 Feb 11;13:21. doi: 10.3389/fncel.2019.00021. eCollection 2019.

4.

Emotions towards magnetic resonance imaging in people with multiple sclerosis.

Engels K, Schiffmann I, Weierstall R, Rahn AC, Daubmann A, Pust G, Chard D, Lukas C, Scheiderbauer J, Stellmann JP, Heesen C.

Acta Neurol Scand. 2019 Jun;139(6):497-504. doi: 10.1111/ane.13082. Epub 2019 Mar 28.

PMID:
30802931
5.

Association between pathological and MRI findings in multiple sclerosis.

Filippi M, Brück W, Chard D, Fazekas F, Geurts JJG, Enzinger C, Hametner S, Kuhlmann T, Preziosa P, Rovira À, Schmierer K, Stadelmann C, Rocca MA; Attendees of the Correlation between Pathological and MRI findings in MS workshop.

Lancet Neurol. 2019 Feb;18(2):198-210. doi: 10.1016/S1474-4422(18)30451-4. Review.

PMID:
30663609
6.

Structural network disruption markers explain disability in multiple sclerosis.

Charalambous T, Tur C, Prados F, Kanber B, Chard DT, Ourselin S, Clayden JD, A M Gandini Wheeler-Kingshott C, Thompson AJ, Toosy AT.

J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):219-226. doi: 10.1136/jnnp-2018-318440. Epub 2018 Nov 22.

7.

New MS diagnostic criteria in practice.

De Angelis F, Brownlee WJ, Chard DT, Trip SA.

Pract Neurol. 2019 Feb;19(1):64-67. doi: 10.1136/practneurol-2018-001945. Epub 2018 Sep 22. No abstract available.

PMID:
30244196
8.

Magnetic resonance imaging as a prognostic disability marker in clinically isolated syndrome: A systematic review.

Rahn AC, Köpke S, Stellmann JP, Schiffmann I, Lukas C, Chard D, Heesen C.

Acta Neurol Scand. 2019 Jan;139(1):18-32. doi: 10.1111/ane.13010. Epub 2018 Sep 6.

PMID:
30091223
9.

Commentary on Al Hussona et al. 'New-onset seizures as a sole clinical presentation of multiple sclerosis'.

Chard DT.

Mult Scler. 2019 Feb;25(2):298-299. doi: 10.1177/1352458518781978. Epub 2018 Jun 19.

PMID:
29916300
10.

Progression of regional grey matter atrophy in multiple sclerosis.

Eshaghi A, Marinescu RV, Young AL, Firth NC, Prados F, Jorge Cardoso M, Tur C, De Angelis F, Cawley N, Brownlee WJ, De Stefano N, Laura Stromillo M, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Geurts JJG, Vrenken H, Wottschel V, Leurs CE, Uitdehaag B, Pirpamer L, Enzinger C, Ourselin S, Gandini Wheeler-Kingshott CA, Chard D, Thompson AJ, Barkhof F, Alexander DC, Ciccarelli O.

Brain. 2018 Jun 1;141(6):1665-1677. doi: 10.1093/brain/awy088.

11.

Response to the commentary of Yates RL and DeLuca GC on the study: HLA-DRB1*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis.

Yaldizli Ö, Sethi V, Pardini M, Tur C, Mok KY, Muhlert N, Liu Z, Samson RS, Wheeler-Kingshott CAM, Yousry TA, Houlden H, Hardy J, Miller DH, Chard DT.

Mult Scler Relat Disord. 2018 Jan;19:168-170. doi: 10.1016/j.msard.2016.08.006. Epub 2016 Aug 12. No abstract available.

PMID:
29409599
12.

Deep gray matter volume loss drives disability worsening in multiple sclerosis.

Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott CAMG, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O; MAGNIMS study group.

Ann Neurol. 2018 Feb;83(2):210-222. doi: 10.1002/ana.25145. Epub 2018 Feb 6.

13.

Resolving the clinico-radiological paradox in multiple sclerosis.

Chard D, Trip SA.

F1000Res. 2017 Oct 12;6:1828. doi: 10.12688/f1000research.11932.1. eCollection 2017. Review.

14.

Commentary on: Neuromyelitis optica spectrum disorder related tonic spams responsive to lacosamide - Authors reply.

Brownlee WJ, Baheerathan A, Rugg-Gunn F, Chard DT, Trip SA.

Mult Scler Relat Disord. 2017 Oct;17:146-147. doi: 10.1016/j.msard.2017.07.021. Epub 2017 Jul 24. No abstract available.

PMID:
29055447
15.

Volumetric reconstruction from printed films: Enabling 30 year longitudinal analysis in MR neuroimaging.

Ebner M, Chung KK, Prados F, Cardoso MJ, Chard DT, Vercauteren T, Ourselin S.

Neuroimage. 2018 Jan 15;165:238-250. doi: 10.1016/j.neuroimage.2017.09.056. Epub 2017 Oct 7.

16.

Contralateral cortico-ponto-cerebellar pathways reconstruction in humans in vivo: implications for reciprocal cerebro-cerebellar structural connectivity in motor and non-motor areas.

Palesi F, De Rinaldis A, Castellazzi G, Calamante F, Muhlert N, Chard D, Tournier JD, Magenes G, D'Angelo E, Gandini Wheeler-Kingshott CAM.

Sci Rep. 2017 Oct 9;7(1):12841. doi: 10.1038/s41598-017-13079-8.

17.

The relationship between cortical lesions and periventricular NAWM abnormalities suggests a shared mechanism of injury in primary-progressive MS.

Pardini M, Petracca M, Harel A, Fleysher L, Oesingmann N, Bommarito G, Fabian M, Chard D, Lublin F, Inglese M.

Neuroimage Clin. 2017 Jul 4;16:111-115. doi: 10.1016/j.nicl.2017.07.001. eCollection 2017.

18.

Neuromyelitis optica spectrum disorder related tonic spasms responsive to lacosamide.

Baheerathan A, Brownlee WJ, Rugg-Gunn F, Chard DT, Trip SA.

Mult Scler Relat Disord. 2017 Apr;13:73-74. doi: 10.1016/j.msard.2017.02.009. Epub 2017 Feb 14.

PMID:
28427706
19.

Antecedent anti-NMDA receptor encephalitis in two patients with multiple sclerosis.

Baheerathan A, Brownlee WJ, Chard DT, Shields K, Gregory R, Trip SA.

Mult Scler Relat Disord. 2017 Feb;12:20-22. doi: 10.1016/j.msard.2016.12.009. Epub 2016 Dec 29.

PMID:
28283100
20.

Reconstructing contralateral fiber tracts: methodological aspects of cerebello-thalamocortical pathway reconstruction.

Palesi F, Tournier JD, Calamante F, Muhlert N, Castellazzi G, Chard D, D'Angelo E, Wheeler-Kingshott CG.

Funct Neurol. 2016 Oct/Dec;31(4):229-238.

21.

An abnormal periventricular magnetization transfer ratio gradient occurs early in multiple sclerosis.

Brown JW, Pardini M, Brownlee WJ, Fernando K, Samson RS, Prados Carrasco F, Ourselin S, Gandini Wheeler-Kingshott CA, Miller DH, Chard DT.

Brain. 2017 Feb;140(2):387-398. doi: 10.1093/brain/aww296. Epub 2017 Jan 2.

22.

A Risk Score for Predicting Multiple Sclerosis.

Dobson R, Ramagopalan S, Topping J, Smith P, Solanky B, Schmierer K, Chard D, Giovannoni G.

PLoS One. 2016 Nov 1;11(11):e0164992. doi: 10.1371/journal.pone.0164992. eCollection 2016.

23.

New oral drugs for the treatment of multiple sclerosis.

Chard D, Trip A, Chataway J.

Br J Hosp Med (Lond). 2016 Sep 2;77(9):502-3. doi: 10.12968/hmed.2016.77.9.502. No abstract available.

PMID:
27640651
24.

Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosis.

Pardini M, Sudre CH, Prados F, Yaldizli Ö, Sethi V, Muhlert N, Samson RS, van de Pavert SH, Cardoso MJ, Ourselin S, Gandini Wheeler-Kingshott CA, Miller DH, Chard DT.

J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1212-1217. doi: 10.1136/jnnp-2016-313979. Epub 2016 Sep 6.

PMID:
27601434
25.

Visualization of cortical MS lesions with MRI need not be further improved - YES.

Geurts JJ, Chard DT.

Mult Scler. 2017 Jan;23(1):15-17. doi: 10.1177/1352458516665498. Epub 2016 Sep 28. No abstract available.

PMID:
27566450
26.

The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?

Vermersch P, Berger T, Gold R, Lukas C, Rovira A, Meesen B, Chard D, Comabella M, Palace J, Trojano M.

Mult Scler. 2016 Aug;22(2 Suppl):18-33. doi: 10.1177/1352458516650739. Review.

PMID:
27465613
27.

Patterns of white matter damage are non-random and associated with cognitive function in secondary progressive multiple sclerosis.

Meijer KA, Cercignani M, Muhlert N, Sethi V, Chard D, Geurts JJ, Ciccarelli O.

Neuroimage Clin. 2016 Jun 14;12:123-31. doi: 10.1016/j.nicl.2016.06.009. eCollection 2016.

28.

Brain atrophy measurements should be used to guide therapy monitoring in MS - Commentary.

Chard D.

Mult Scler. 2016 Oct;22(12):1526-1527. Epub 2016 Jun 22. No abstract available.

PMID:
27335097
29.

HLA-DRB*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis.

Yaldizli Ö, Sethi V, Pardini M, Tur C, Mok KY, Muhlert N, Liu Z, Samson RS, Wheeler-Kingshott CA, Yousry TA, Houlden H, Hardy J, Miller DH, Chard DT.

Mult Scler Relat Disord. 2016 May;7:47-52. doi: 10.1016/j.msard.2016.03.003. Epub 2016 Mar 7.

PMID:
27237756
30.

What lies beneath grey matter atrophy in multiple sclerosis?

Chard DT, Miller DH.

Brain. 2016 Jan;139(Pt 1):7-10. doi: 10.1093/brain/awv354. No abstract available.

PMID:
26747854
31.

White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis.

Meijer KA, Muhlert N, Cercignani M, Sethi V, Ron MA, Thompson AJ, Miller DH, Chard D, Geurts JJ, Ciccarelli O.

Mult Scler. 2016 Oct;22(11):1429-1437. Epub 2016 Jan 5.

PMID:
26733423
32.

Multi-channel registration of fractional anisotropy and T1-weighted images in the presence of atrophy: application to multiple sclerosis.

Roura E, Schneider T, Modat M, Daga P, Muhlert N, Chard D, Ourselin S, Lladó X, Gandini Wheeler-Kingshott C.

Funct Neurol. 2015 Oct-Dec;30(4):245-56.

33.

The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis.

Yaldizli Ö, Penner IK, Yonekawa T, Naegelin Y, Kuhle J, Pardini M, Chard DT, Stippich C, Kira JI, Bendfeldt K, Amann M, Radue EW, Kappos L, Sprenger T.

Eur J Neurol. 2016 Mar;23(3):510-9. doi: 10.1111/ene.12891. Epub 2015 Nov 19.

PMID:
26699999
34.

The role of MRI in the evaluation of secondary progressive multiple sclerosis.

Brown JW, Chard DT.

Expert Rev Neurother. 2016;16(2):157-71. doi: 10.1586/14737175.2016.1134323. Epub 2016 Jan 22. Review. Erratum in: Expert Rev Neurother. 2016;16(4):463.

PMID:
26692498
35.

White and gray matter damage in primary progressive MS: The chicken or the egg?

Bodini B, Chard D, Altmann DR, Tozer D, Miller DH, Thompson AJ, Wheeler-Kingshott C, Ciccarelli O.

Neurology. 2016 Jan 12;86(2):170-6. doi: 10.1212/WNL.0000000000002237. Epub 2015 Dec 16.

36.

Motor network efficiency and disability in multiple sclerosis.

Pardini M, Yaldizli Ö, Sethi V, Muhlert N, Liu Z, Samson RS, Altmann DR, Ron MA, Wheeler-Kingshott CA, Miller DH, Chard DT.

Neurology. 2015 Sep 29;85(13):1115-22. doi: 10.1212/WNL.0000000000001970. Epub 2015 Aug 28.

37.

A longitudinal study of cortical grey matter lesion subtypes in relapse-onset multiple sclerosis.

Sethi V, Yousry T, Muhlert N, Tozer DJ, Altmann D, Ron M, Wheeler-Kingshott C, Miller DH, Chard DT.

J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):750-3. doi: 10.1136/jnnp-2015-311102. Epub 2015 Aug 13.

38.

Characteristics of lesional and extra-lesional cortical grey matter in relapsing-remitting and secondary progressive multiple sclerosis: A magnetisation transfer and diffusion tensor imaging study.

Yaldizli Ö, Pardini M, Sethi V, Muhlert N, Liu Z, Tozer DJ, Samson RS, Wheeler-Kingshott CA, Yousry TA, Miller DH, Chard DT.

Mult Scler. 2016 Feb;22(2):150-9. doi: 10.1177/1352458515586085. Epub 2015 May 26.

PMID:
26014608
39.

DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?

van de Pavert SH, Muhlert N, Sethi V, Wheeler-Kingshott CA, Ridgway GR, Geurts JJ, Ron M, Yousry TA, Thompson AJ, Miller DH, Chard DT, Ciccarelli O.

J Neurol Neurosurg Psychiatry. 2016 May;87(5):461-7. doi: 10.1136/jnnp-2014-310142. Epub 2015 Apr 29.

40.

Magnetization transfer ratio measures in normal-appearing white matter show periventricular gradient abnormalities in multiple sclerosis.

Liu Z, Pardini M, Yaldizli Ö, Sethi V, Muhlert N, Wheeler-Kingshott CA, Samson RS, Miller DH, Chard DT.

Brain. 2015 May;138(Pt 5):1239-46. doi: 10.1093/brain/awv065. Epub 2015 Mar 29.

41.

Cervical cord area measurement using volumetric brain magnetic resonance imaging in multiple sclerosis.

Liu Z, Yaldizli Ö, Pardini M, Sethi V, Kearney H, Muhlert N, Wheeler-Kingshott C, Miller DH, Chard DT.

Mult Scler Relat Disord. 2015 Jan;4(1):52-7. doi: 10.1016/j.msard.2014.11.004. Epub 2014 Nov 18.

PMID:
25787053
42.

MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis.

Gass A, Rocca MA, Agosta F, Ciccarelli O, Chard D, Valsasina P, Brooks JC, Bischof A, Eisele P, Kappos L, Barkhof F, Filippi M; MAGNIMS Study Group.

Lancet Neurol. 2015 Apr;14(4):443-54. doi: 10.1016/S1474-4422(14)70294-7. Epub 2015 Mar 4. Review.

PMID:
25748099
43.

Paradoxes in thalamic function and cognition in people with multiple sclerosis: less is more.

Chard DT, Benedict RH.

Neurology. 2015 Feb 24;84(8):764-5. doi: 10.1212/WNL.0000000000001293. Epub 2015 Jan 23. No abstract available.

PMID:
25616482
44.

Predicting outcome in clinically isolated syndrome using machine learning.

Wottschel V, Alexander DC, Kwok PP, Chard DT, Stromillo ML, De Stefano N, Thompson AJ, Miller DH, Ciccarelli O.

Neuroimage Clin. 2014 Dec 4;7:281-7. doi: 10.1016/j.nicl.2014.11.021. eCollection 2015.

45.

Regional patterns of grey matter atrophy and magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups: a voxel-based analysis study.

Mallik S, Muhlert N, Samson RS, Sethi V, Wheeler-Kingshott CA, Miller DH, Chard DT.

Mult Scler. 2015 Apr;21(4):423-32. doi: 10.1177/1352458514546513. Epub 2014 Aug 21.

46.

Contralateral cerebello-thalamo-cortical pathways with prominent involvement of associative areas in humans in vivo.

Palesi F, Tournier JD, Calamante F, Muhlert N, Castellazzi G, Chard D, D'Angelo E, Wheeler-Kingshott CA.

Brain Struct Funct. 2015 Nov;220(6):3369-84. doi: 10.1007/s00429-014-0861-2. Epub 2014 Aug 19.

47.

The grey matter correlates of impaired decision-making in multiple sclerosis.

Muhlert N, Sethi V, Cipolotti L, Haroon H, Parker GJ, Yousry T, Wheeler-Kingshott C, Miller D, Ron M, Chard D.

J Neurol Neurosurg Psychiatry. 2015 May;86(5):530-6. doi: 10.1136/jnnp-2014-308169. Epub 2014 Jul 8.

48.

Cortical lesion counts by double inversion recovery should be part of the MRI monitoring process for all MS patients: no.

Chard D.

Mult Scler. 2014 Apr;20(5):539-40. doi: 10.1177/1352458514526946. No abstract available.

PMID:
24692504
49.

Accurate GM atrophy quantification in MS using lesion-filling with co-registered 2D lesion masks.

Popescu V, Ran NC, Barkhof F, Chard DT, Wheeler-Kingshott CA, Vrenken H.

Neuroimage Clin. 2014 Jan 18;4:366-73. doi: 10.1016/j.nicl.2014.01.004. eCollection 2014.

50.

Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups.

Samson RS, Cardoso MJ, Muhlert N, Sethi V, Wheeler-Kingshott CA, Ron M, Ourselin S, Miller DH, Chard DT.

Mult Scler. 2014 Sep;20(10):1322-30. doi: 10.1177/1352458514522537. Epub 2014 Feb 19.

PMID:
24552746

Supplemental Content

Support Center